Would you offer adjuvant abemaciclib to young, premenopausal women desiring more children who meet criteria for the same based on monarchE trial?

Based on the package insert for abemaciclib, there is no reported risk of early menopause or amenorrhea. CDK4/6 inhibitors are cytostatic (by blocking the transition from G1 to S phase) and not cytotoxic, unlike alkylating chemotherapy. So, I would feel comfortable offering abemaciclib and subsequen...